Transgene SA 2017 IR
The report highlights Transgene's progress in 2017, including the launch of ten clinical trials for its five immunotherapy products in clinical development. The company signed key clinical collaborations with Bristol-Myers Squibb, Randox, BioInvent, and Servier. Transgene also launched its patented Invir.IO platform to design a new generation of multifunctional oncolytic viruses. Financially, the company secured a private placement of 14 million Euros, extending its financial visibility until mid-2019.
Company: Transgene SA
Sector: Professional & technical services
Country: France
Year: 2017
Type: IR
Pages: 200
Back to company
Transgene SA
Registration Document
The report highlights Transgene's progress in 2017, including the launch of ten clinical trials for its five immunotherapy products in clinical development. The company signed key clinical collaborations with Bristol-Myers Squibb, Randox, BioInvent, and Servier. Transgene also launched its patented Invir.IO platform to design a new generation of multifunctional oncolytic viruses. Financially, the company secured a private placement of 14 million Euros, extending its financial visibility until mid-2019.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Published
Apr 6, 2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Employees